Amylyx Pharmaceuticals, Inc. Total Shareholder Rtn Amt
Amylyx Pharmaceuticals, Inc. (AMLX) reported Total Shareholder Rtn Amt of $67 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-23.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-23
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $67.00 DEF 14A · filed 2026-04-23 |
| 2024-12-31 | $21.00 DEF 14A · filed 2026-04-23 |
| 2023-12-31 | $81.00 DEF 14A · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |